

Follow-Up Adverse Event Review: Benazepril

**Pediatric Advisory Committee Meeting
March 25, 2008**

**Amy M. Taylor, MD, MHS, FAAP
Medical Officer
Pediatric and Maternal Health Staff
Office of New Drugs
Food and Drug Administration**



Background Drug Information

- **Drug:** Lotensin[®] (benazepril HCL) Tablets
- **Therapeutic Category:** ACE Inhibitor
- **Sponsor:** Novartis Pharmaceutical Corporation
- **Indication (pediatric):** Treatment of hypertension, age \geq 6 years
- **Original Market Approval:** June 25, 1991
- **Pediatric Exclusivity Granted:** July 2, 2003
- **Previous PAC AE Review:** February 14, 2005

Pediatric Adverse Events Since Market Approval (n=6)

2 cases presented in February 2005

- Hyperchloremic metabolic acidosis secondary to hypoaldosteronism in 4 year old
- Accidental ingestion by 2 year old

2005 PAC requested continued focus review of adverse events and follow-up based on lack of reports during initial reporting period

Pediatric Adverse Events Since Market Approval (n=6)

2 cases presented in 2005

1 duplicate case

3 remaining cases:

- 1 year old male on benazepril for 9 days hospitalized with increased serum creatinine and potassium. No additional information.

Pediatric Adverse Events Since Market Approval (n=6)

2 cases of congenital abnormalities

- Newborn with in utero exposure (1st trimester) delivered at 36 weeks with multiple cardiac defects and unilateral renal agenesis with a single dysplastic kidney. Died at 19 days due to pulmonary hemorrhage and congenital heart disease.
- Premature infant (gestational age unknown) with in utero exposure (1st trimester) with “hypotrophy, premature jaundice and surfactant pulmonary troubles”.

Lotensin[®] Boxed Warning

Lotensin[®] labeling has a boxed warning stating that ACE inhibitors can cause injury and even death to the developing fetus and should be discontinued as soon as possible.

Summary: Benazepril

- No safety signals identified since market approval unique to the pediatric population.
- Pediatric use (< 1% of all prescriptions)¹
- This completes the follow-up report to the 1-year AE review.
- FDA recommends routine monitoring of AEs for benazepril in all populations.

Does the Advisory Committee concur?

Acknowledgements

OSE

- Monika Houstoun
- Kendra Worthy
- Ann McMahan
- Laura Governale

DCRP

- Abraham Karkowsky

PMHS

- Denise Pica-Branco
- Lisa Mathis

OPT

- Judith Cope
- Debbie Avant
- Dianne Murphy